BioNTech SE reported revenues of €1,289.2 million and a net profit of €184.5 million for the three months ended September 30, 2026. For the nine-month period, revenues totaled €1,512.9 million with a net loss of €1,168.2 million. The company operates in the biotechnology and immunotherapy sector.
